Minerva Neurosciences (NERV) Competitors $1.77 -0.02 (-1.06%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NERV vs. VTVT, ARTV, RNXT, CELU, PEPG, MRSN, BLUE, CUE, AADI, and NBRVShould you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include vTv Therapeutics (VTVT), Artiva Biotherapeutics (ARTV), RenovoRx (RNXT), Celularity (CELU), PepGen (PEPG), Mersana Therapeutics (MRSN), bluebird bio (BLUE), Cue Biopharma (CUE), Aadi Bioscience (AADI), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry. Minerva Neurosciences vs. Its Competitors vTv Therapeutics Artiva Biotherapeutics RenovoRx Celularity PepGen Mersana Therapeutics bluebird bio Cue Biopharma Aadi Bioscience Nabriva Therapeutics Minerva Neurosciences (NASDAQ:NERV) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk. Do insiders & institutionals believe in NERV or VTVT? 34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 8.6% of Minerva Neurosciences shares are held by insiders. Comparatively, 4.2% of vTv Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend NERV or VTVT? Minerva Neurosciences currently has a consensus price target of $5.00, indicating a potential upside of 173.97%. vTv Therapeutics has a consensus price target of $35.50, indicating a potential upside of 129.62%. Given Minerva Neurosciences' higher probable upside, research analysts plainly believe Minerva Neurosciences is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, NERV or VTVT? vTv Therapeutics has higher revenue and earnings than Minerva Neurosciences. vTv Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$30M$0.822.23vTv Therapeutics$17K2,905.57-$20.25M-$3.01-5.14 Which has more risk and volatility, NERV or VTVT? Minerva Neurosciences has a beta of -0.37, suggesting that its stock price is 137% less volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Does the MarketBeat Community believe in NERV or VTVT? vTv Therapeutics received 6 more outperform votes than Minerva Neurosciences when rated by MarketBeat users. Likewise, 57.12% of users gave vTv Therapeutics an outperform vote while only 55.52% of users gave Minerva Neurosciences an outperform vote. CompanyUnderperformOutperformMinerva NeurosciencesOutperform Votes34755.52% Underperform Votes27844.48% vTv TherapeuticsOutperform Votes35357.12% Underperform Votes26542.88% Is NERV or VTVT more profitable? Minerva Neurosciences' return on equity of 0.00% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -6.74% vTv Therapeutics N/A -184.64%-47.29% Does the media prefer NERV or VTVT? In the previous week, vTv Therapeutics had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 3 mentions for vTv Therapeutics and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.94 beat vTv Therapeutics' score of 0.62 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Minerva Neurosciences Positive vTv Therapeutics Positive SummaryvTv Therapeutics beats Minerva Neurosciences on 9 of the 16 factors compared between the two stocks. Get Minerva Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NERV vs. The Competition Export to ExcelMetricMinerva NeurosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.76M$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E Ratio-4.158.5527.1919.64Price / SalesN/A262.61408.78152.17Price / CashN/A65.8538.3234.64Price / Book-0.456.536.974.60Net Income-$30M$143.48M$3.23B$248.06M7 Day Performance-0.22%0.20%-0.88%-1.02%1 Month Performance11.96%10.93%7.81%3.51%1 Year Performance-44.86%2.46%31.53%12.68% Minerva Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NERVMinerva Neurosciences3.4135 of 5 stars$1.83+2.2%$5.00+174.0%-45.1%$12.76MN/A-4.159Positive NewsVTVTvTv Therapeutics1.6837 of 5 stars$16.10-1.3%$35.50+120.5%-24.8%$51.44M$17K-3.559Positive NewsARTVArtiva Biotherapeutics2.6337 of 5 stars$2.11+0.5%$19.40+819.4%N/A$51.41M$251K0.0081Analyst UpgradeAnalyst RevisionGap UpRNXTRenovoRx2.9553 of 5 stars$1.37-1.4%$7.25+429.2%+16.2%$50.10M$240K-2.406Short Interest ↓Gap UpCELUCelularity0.53 of 5 stars$1.98-4.8%N/A-45.7%$49.81M$54.22M-0.75220Gap DownPEPGPepGen2.7389 of 5 stars$1.52+1.3%$7.67+404.4%-91.7%$49.08MN/A-0.5130Trending NewsMRSNMersana Therapeutics4.1293 of 5 stars$0.39+1.3%$5.20+1,230.6%-84.0%$48.71M$34.01M-0.64150BLUEbluebird bio3.3895 of 5 stars$4.97flat$44.60+797.4%N/A$48.67M$103.95M-0.13520Positive NewsCUECue Biopharma4.4693 of 5 stars$0.64-0.6%$3.00+371.0%-57.6%$48.00M$7.99M-0.7160AADIAadi Bioscience0.5974 of 5 stars$1.87+11.3%$1.67-10.9%+17.6%$46.18M$25.07M-0.8240NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies vTv Therapeutics Alternatives Artiva Biotherapeutics Alternatives RenovoRx Alternatives Celularity Alternatives PepGen Alternatives Mersana Therapeutics Alternatives bluebird bio Alternatives Cue Biopharma Alternatives Aadi Bioscience Alternatives Nabriva Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NERV) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NERV Stock Free NERV Stock Alerts